All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given.  View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

What is the outcome of transplantation in fit patients over 64 years?

Featured:

Gabriele Magliano

Apr 9, 2021


During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Gabriele Magliano, Università Cattolica del Sacro Cuore, Rome, IT. We asked, What is the outcome of transplantation in fit patients over 64 years?

What is the outcome of transplantation in fit patients over 64 years?

In this video, Magliano discusses allogeneic hematopoietic stem cell transplantation outcomes for fit patients with AML over the age of 64. He explains that nowadays, age is not the main factor influencing whether patients achieve complete remission, but rather their overall clinical presentation. Magliano outlines the results of recent cohort trials on geriatric patients with AML and remains hopeful for future therapies.

 

More about...